Clinical Trial Update: A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer [Phase 1]

View source ↗

Summary

A Phase 1 neoadjuvant trial evaluating paricalcitol to modify the tumor microenvironment in resectable pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Paricalcitol (paricalcitol)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Adenocarcinoma of the Pancreas | Phase 1 | Status: COMPLETED